Imiquimod: an immune response modifier in the treatment of precancerous skin lesions and skin cancer

Author： Papadavid Evangelia   Stratigos Alexandros J   Falagas Matthew E  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.8, Iss.11, 2007-08, pp. : 1743-1755

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The small-molecule immune response modifier imiquimod – its mode of action and clinical use in the treatment of skin cancer

By Schön Michael P   Schön Margarete  

Expert Opinion on Therapeutic Targets, Vol. 10, Iss. 1, 2006-02 ,pp. : 69-76

Informa Healthcare

Access to resources Recommend Favorite

The Role of Topical Immune Response Modifiers in Skin Cancer

By Woodmansee Courtney   Pillow Jessica   Skinner Robert B.  

Drugs, Vol. 66, Iss. 13, 2006-01 ,pp. : 1657-1664

Adis International

Access to resources Recommend Favorite

Response to Letter: Skin Cancer Treatment Fee Comparisons Not Inaccurate

By Wilson Leslie S.   Basu Rituparna   Asgari Maryam   Chren Mary-Margaret  

Dermatologic Surgery, Vol. 38, Iss. 12, 2012-12 ,pp. : 2039-2041

Elsevier

Access to resources Recommend Favorite

Topical Imiquimod: A Review of its Use in the Management of Anogenital Warts, Actinic Keratoses, Basal Cell Carcinoma and Other Skin Lesions

By Wagstaff Antona J.   Perry Caroline M.  

Drugs, Vol. 67, Iss. 15, 2007-01 ,pp. : 2187-2210

Adis International

Access to resources Recommend Favorite

Skin cancer: prevalence, prevention and treatment

By Sharpe Graham  

Clinical Medicine, Vol. 6, Iss. 4, 2006-07 ,pp. : 333-334

Royal College Of Physicians

Access to resources Recommend Favorite